👉CRDL is TODAY’S #1 ALERT 👈

Hey Folks, Jeff Bishop here.

We’re fresh on the heels of yesterday’s “tactical trade” idea, which made a peak 13.5% gain on the day.

Today’s idea is one you need to get on your radar right away.

💥Cardiol Therapeutics Inc. (CRDL) is a company developing therapies for the treatment of heart disease.

Just this morning, it released topline results for its major, Phase II clinical trial in patients with acute myocarditis. 

The company’s lead candidate, CardiolRx™, “showed a notable improvement” in one of the two primary endpoints by reducing extracellular volume.

This “was associated with improvements over placebo in multiple pre-specified cardiac magnetic resonance imaging (“CMR”) endpoints, including a significant reduction in [left ventricular] mass.”

The drug was also “shown to be safe and well tolerated.”

The company said the trial results “provide compelling clinical proof of concept for CardiolRx™ and strongly support advancing the clinical development of CardiolRx™ and CRD-38 in cardiomyopathies, heart failure, and myocarditis.”

For a small, pre-commercial pharma company like CRDL, an announcement like this can be a real catalyst.

💥I’m dialed into CRDL today to see how investors react to the news.

👉CRDL is TODAY’S #1 ALERT👈

CRDL is a clinical-stage life sciences company developing cannabidiol-based products to treat heart diseases.

In the wake of COVID, pericarditis and myocarditis have become household names…

Most people now know that these are inflammatory heart conditions that can significantly impact quality of life — and sometimes even prove fatal.

What they don’t know is that these conditions have very few effective treatments. 

Collaborating with world-renowned medical institutions such as the Mayo Clinic and Cleveland Clinic, CRDL is working to address these significant unmet needs.

Importantly, many studies have shown that cannabidiol (CBD) can inhibit several inflammatory pathways, especially those activated in pericarditis and myocarditis.

The company’s lead drug candidate is a novel, pharmaceutically manufactured oral cannabidiol product named CardiolRx™ that has already been granted U.S. FDA orphan drug designation (ODD) for treatment of pericarditis, including recurrent pericarditis.

Pericarditis: Phase II Success ✅, Phase III Underway

CardiolRx™ has successfully completed its Phase II MAvERIC-Pilot study for recurrent pericarditis (RP), chaired by Dr. Allan Klein, who is the director of the Center for the Diagnosis and Treatment of Pericardial Diseases at the Cleveland Clinic — one of the largest pericardial disease centers in the world.

CRDL picked the right doctor for the job. Dr. Klein was also the principal investigator for the Phase III trial of Arcalyst (Rilonacept), the first FDA-approved drug with an indication specifically for RP. 

Not only does Arcalyst have an extraordinary price tag of $270,000 per patient per year, it can also suppress the immune system, potentially causing serious infections.

Nevertheless, following its debuting in 2021, Rilonacept generated an impressive $233.2 million in 2023, and $417 million in 2024. For 2025, Rilonacept’s net product revenue is expected to be over $625 million.

Clearly, this market is ripe for competition.

CRDL’s MAvERIC-Pilot study wrapped in late 2024, with full results presented at the American Heart Association Scientific Sessions.

The data showed rapid and durable reductions in pericarditis pain, inflammation, and recurrence, with excellent safety and tolerability.

Building on that success, CRDL launched its pivotal Phase III MAVERIC trial in April 2025, aiming to enroll approximately 110 patients across approximately 20 clinical sites in North America and Europe.

Myocarditis: Topline Results Are In 🫀 

CRDL’s other Phase II trial — ARCHER — targeted acute myocarditis (AM) and was chaired by Dr. Dennis McNamara, director of the heart failure/transplantation program at the University of Pittsburgh Medical Center. 

Right now, there are no FDA-approved therapies for acute myocarditis, so there is a major unmet need here — despite an estimated 46,000 AM cases each year in the US.

The trial reached full enrollment (100 patients) in September 2024 at 34 clinical sites in the United States, Canada, France, Brazil, and Israel. 

As mentioned above, topline results from Phase II were released this morning with the bottom line that they “strongly support advancing the clinical development of CardiolRx™ and CRD-38 in cardiomyopathies, heart failure, and myocarditis.”

Final Thoughts

CRDL has reported $30.6 million in cash and cash equivalents as of December 31, 2024, providing a runway into Q3 2026.

The stock has received three BUY ratings since April:

That’s an average upside of 603%.

For more on the company and its potentially breakthrough therapies, check out this excellent presentation the company released this month.

And of course, always approach your trading in a responsible manner,  remembering that trading is very risky. Nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this email as well, so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom line: Analysts already saw multibagger potential in CRDL before its big trial results that came out this morning.

💥I’m locked into CRDL right now to see how investors react to the big news. Be sure to tune in!

To Your Success,

Jeff Bishop

*DISCLAIMER: This entity is owned by Sherwood Ventures LLC (SV). To more fully understand any SV subscription, website, application or other service, please review our full disclaimer located at https://bullseyealerts.com/disclaimer/

Just so you know, what you’re reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let’s be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren’t what you’d call “typical.”

Just a quick heads up about this ad you’re reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received fifteen thousand dollars (cash) from Legends Media for advertising Cardiol Therapeutics Inc for a one day marketing program starting on August 6, 2025.  Prior to this, we received seventeen thousand five hundred dollars (cash) from Shore Thing Media for advertising Cardiol Therapeutics Inc for a one day marketing program on June 12, 2024. It might seem obvious, but while our client claims not to own any shares in Cardiol Therapeutics Inc, whoever ultimately paid them most likely owns shares. You should assume they are looking to sell some or all of them at any time after we send out this information, which might negatively affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither Sherwood Ventures nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as the marketing campaign ends, though that is not always the case.

Now, diving right into Cardiol Therapeutics Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there’s exceptional risk involved in trading. This isn’t small potatoes we’re talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We’re shining a light on the good stuff about the company here, but it’s on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we’re not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies who are paying us and we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can’t wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who’s licensed to give you real advice. To be clear, 

Neither Sherwood Ventures nor its owners, employees, or independent contractors are registered as a securities broker-dealer, broker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulatory authority, or any self-regu1atory organization.

So, that’s the scoop! If you’re intrigued and want to learn more about the companies we talk about, hit up the SEC’s website to dig into their filings and see the full picture.